IDH-mutant astrocytoma with EGFR amplification - Genomic profiling in four cases and review of literature

Melissa Umphlett; Khawaja Hasan Bilal; Michael L. Martini; Abigail K. Suwala; Sadhna Ahuja; Omid Rashidipour; Isabelle Germano; Matija Snuderl; Peter Morgenstern; Nadejda M. Tsankova

doi:10.1093/noajnl/vdac067

IDH-mutant astrocytoma with EGFR amplification - Genomic profiling in four cases and review of literature

Melissa Umphlett, Khawaja Hasan Bilal, Michael L. Martini, Abigail K. Suwala, Sadhna Ahuja, Omid Rashidipour, Isabelle Germano, Matija Snuderl, Peter Morgenstern, Nadejda M. Tsankova

Research output: Contribution to journal › Article › peer-review

Abstract

IDH-mutant astrocytomas carry significantly better prognosis compared to their IDH-wildtype grade 4 (glioblastoma) counterpart. Several molecular diagnostic markers have emerged in the 2021 CNS WHO classification, with powerful prognostic implications to consider when classifying diffuse IDH-mutant astrocytomas.1-3 EGFR amplification status, associated with aggressive glioma behavior4 and now regarded as a molecular feature of glioblastoma, is not currently a diagnostic consideration in IDH-mutant astrocytomas.1 Although uncommon, IDH-mutant astrocytomas with EGFR amplification exist in large published datasets but their relevance has been underemphasized and remains poorly understood.

Original language	English
Article number	vdac067
Journal	Neuro-Oncology Advances
Volume	4
Issue number	1
DOIs	https://doi.org/10.1093/noajnl/vdac067
State	Published - 1 Jan 2022

Access to Document

10.1093/noajnl/vdac067

Cite this

@article{6ae4571254e04a28940bd8fef5d5f24f,

title = "IDH-mutant astrocytoma with EGFR amplification - Genomic profiling in four cases and review of literature",

abstract = "IDH-mutant astrocytomas carry significantly better prognosis compared to their IDH-wildtype grade 4 (glioblastoma) counterpart. Several molecular diagnostic markers have emerged in the 2021 CNS WHO classification, with powerful prognostic implications to consider when classifying diffuse IDH-mutant astrocytomas.1-3 EGFR amplification status, associated with aggressive glioma behavior4 and now regarded as a molecular feature of glioblastoma, is not currently a diagnostic consideration in IDH-mutant astrocytomas.1 Although uncommon, IDH-mutant astrocytomas with EGFR amplification exist in large published datasets but their relevance has been underemphasized and remains poorly understood.",

author = "Melissa Umphlett and Bilal, {Khawaja Hasan} and Martini, {Michael L.} and Suwala, {Abigail K.} and Sadhna Ahuja and Omid Rashidipour and Isabelle Germano and Matija Snuderl and Peter Morgenstern and Tsankova, {Nadejda M.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.",

year = "2022",

month = jan,

day = "1",

doi = "10.1093/noajnl/vdac067",

language = "English",

volume = "4",

journal = "Neuro-Oncology Advances",

issn = "2632-2498",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - IDH-mutant astrocytoma with EGFR amplification - Genomic profiling in four cases and review of literature

AU - Umphlett, Melissa

AU - Bilal, Khawaja Hasan

AU - Martini, Michael L.

AU - Suwala, Abigail K.

AU - Ahuja, Sadhna

AU - Rashidipour, Omid

AU - Germano, Isabelle

AU - Snuderl, Matija

AU - Morgenstern, Peter

AU - Tsankova, Nadejda M.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - IDH-mutant astrocytomas carry significantly better prognosis compared to their IDH-wildtype grade 4 (glioblastoma) counterpart. Several molecular diagnostic markers have emerged in the 2021 CNS WHO classification, with powerful prognostic implications to consider when classifying diffuse IDH-mutant astrocytomas.1-3 EGFR amplification status, associated with aggressive glioma behavior4 and now regarded as a molecular feature of glioblastoma, is not currently a diagnostic consideration in IDH-mutant astrocytomas.1 Although uncommon, IDH-mutant astrocytomas with EGFR amplification exist in large published datasets but their relevance has been underemphasized and remains poorly understood.

AB - IDH-mutant astrocytomas carry significantly better prognosis compared to their IDH-wildtype grade 4 (glioblastoma) counterpart. Several molecular diagnostic markers have emerged in the 2021 CNS WHO classification, with powerful prognostic implications to consider when classifying diffuse IDH-mutant astrocytomas.1-3 EGFR amplification status, associated with aggressive glioma behavior4 and now regarded as a molecular feature of glioblastoma, is not currently a diagnostic consideration in IDH-mutant astrocytomas.1 Although uncommon, IDH-mutant astrocytomas with EGFR amplification exist in large published datasets but their relevance has been underemphasized and remains poorly understood.

UR - http://www.scopus.com/inward/record.url?scp=85134922546&partnerID=8YFLogxK

U2 - 10.1093/noajnl/vdac067

DO - 10.1093/noajnl/vdac067

M3 - Article

AN - SCOPUS:85134922546

VL - 4

JO - Neuro-Oncology Advances

JF - Neuro-Oncology Advances

SN - 2632-2498

IS - 1

M1 - vdac067

ER -

IDH-mutant astrocytoma with EGFR amplification - Genomic profiling in four cases and review of literature

Abstract

Access to Document

Fingerprint

Cite this